PKQuest: capillary permeability limitation and plasma protein binding – application to human inulin, dicloxacillin and ceftriaxone pharmacokinetics by Levitt, David G
BioMed  Central
Page 1 of 11
(page number not for citation purposes)
BMC Clinical Pharmacology
Open Access BMC Clinical Pharmacology  2002,  2 x Research article
PKQuest: capillary permeability limitation and plasma protein 
binding – application to human inulin, dicloxacillin and ceftriaxone 
pharmacokinetics
David G Levitt
Address: Department of Physiology, University of Minnesota, 6-125 Jackson Hall, 321 Church St. S. E., Minneapolis, MN 55455, USA
E-mail: levitt@dcmir.med.umn.edu
Abstract
Background:  It is generally assumed that the tissue exchange of antibiotics is flow limited
(complete equilibration between the capillary and the tissue water). This assumption may not be
valid if there is a large amount of plasma protein binding because the effective capillary permeability
depends on the product of the intrinsic capillary permeability (PS) and the fraction of solute that is
free in the blood (fwB). PKQuest, a new generic physiologically based pharmacokinetic software
routine (PBPK), provides a novel approach to modeling capillary permeability in which the only
adjustable parameter is the PS of muscle.
Methods: All the results were obtained by applying PKQuest to previously published human
pharmacokinetic data.
Results: The PKQuest analysis suggests that the highly protein bound antibiotics dicloxacillin and
ceftriaxone have a significant capillary permeability limitation. The human muscle capillary PS of
inulin, dicloxacillin and ceftriaxone was 0.6, 13 and 6 ml/min/100 gm, respectively. The ceftriaxone
protein binding is non-linear, saturating at high plasma concentrations. The experimental
ceftriaxone data over a wide range of intravenous inputs (0.15 to 3 gms) was well described by
PKQuest. PKQuest is the first PBPK that includes both permeability limitation and non-linear
binding.
Conclusions: Because of their high degree of plasma protein binding, dicloxacillin and ceftriaxone
appear to have a diffusion limited exchange rate between the blood and tissue and are not flow
limited as had been previously assumed. PKQuest and all the examples are freely available at
[http:\\www.pkquest.com].
Background
The goal of physiologically based pharmacokinetic mod-
els (PBPK) is to describe the whole body drug distribution
and metabolism in terms of an accurate physiological
model of the animal. The most difficult component to
model is the description of the exchange between the
blood and tissue. This is a complicated process, involving,
e.g., transport across the capillary and tissue cell mem-
branes and diffusion in the extravascular and cellular
space. Because of this complexity, some simplifying as-
sumptions must be made in order to incorporate it into a
PBPK. PKQuest is a new general purpose PBPK software
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routine that has previously been used to model the hu-
man pharmacokinetics of propranolol [1], D2O and etha-
nol [2], and the volatile solutes and anesthetics [3]. In
PKQuest, this blood-tissue exchange for organ i is charac-
terized by the parameter fclear [i] defined by (see [1] for
details):
(1)   fclear [i] = (cA - cV)/(cA - cT)
where cA, cV and cT are the free water concentrations in the
artery entering the tissue, the vein leaving it, and the (as-
sumed) well mixed tissue space, respectively. Fclear is a
measure of the fraction of solute that equilibrates with the
tissue in one pass through the capillary. In the limiting
case where the capillary is impermeable, cA = cV and fclear
= 0. At the opposite extreme, where exchange is very fast
and the venous concentration equilibrates with the tissue,
cV = cT and fclear = 1. This latter case is referred to as "flow-
limited" because the blood-tissue exchange becomes lim-
ited by the blood flow. Flow limitation simplifies the
PBPK because it eliminates the necessity of having to de-
termine the value of fclear [i]. Because of this simplicity,
the vast majority of PBPKs in the literature assume that the
exchange is flow limited [4].
The parameter fclear [i] (eq. 1) of organ i can be related to
the capillary permeability-surface area product (PSi, liters/
min/Kg) by the relation (see [1] for derivation):
where fwB is the fraction free in the blood, Fi is the organ
blood flow (liters/min/Kg), wfractB is the fraction of water
in the blood (liters/Kg) and B is the blood density. As the
permeability PS becomes large, fclear approaches 1 (the
flow-limited condition). It can be seen from eq. 2 that the
value of fclear [i] depends on 3 different physiological
PBPK parameters (PSi, Fi, and fwB). The design of PKQuest
implements a unique feature that makes it easy for the
user to test whether the solute under study has some sig-
nificant capillary permeability limitation. PKQuest has
preprogrammed the relative values of PSi for organ i rela-
tive to the value of PSmuscle of the muscle capillaries based
on previous experimental measurements (reviewed in
Crone and Levitt, [5]). Thus, the capillary permeability for
all the organs is determined by just one adjustable param-
eter, the fclear for muscle. PKQuest uses this value of fclear
[muscle] to find PSmuscle from eq. 2, uses the stored ratios
PSi/PSmuscle to find the value of PSi, and then uses eq. 2 to
find the value of fclear [i] for all the other organs. In addi-
tion to simplifying the implementation of the capillary
permeability limitation, this also has the major advantage
that it ensures that the values of fclear [i] for the different
organs are correctly adjusted for the organ blood flow (Fi)
and fraction free in blood (fwB) and have the appropriate
PS value relative to muscle.
All previous PBPK analysis of antibiotics have assumed
that the antibiotic was flow limited. It can be seen from
eq.2 that the value of fclear is determined by the product
of the intrinsic capillary permeability (PS) and the frac-
tion of drug that is free in the blood water (fwB). This im-
plies that drugs that have a high degree of binding (small
fwB) are especially likely to have some capillary permea-
bility limitation (i.e., not flow limited). The two antibiot-
ics that are investigated in this paper (dicloxacillin and
ceftriaxone) were chosen as likely candidates for having
some permeability limitation because they have a high de-
gree of protein binding (small fwB) and they are both rel-
atively lipid insoluble so that one would predict that they
would not have high intrinsic PS values.
Ceftriaxone has the additional complication that the pro-
tein binding is non-linear, saturating at high concentra-
tions. Incorporating non-linear binding greatly
complicates the kinetic equations (see [1] for details) and
for, this reason, is not included in most PBPKs. A notable
exception is the investigation by Tsuji et. al. [6] of the ki-
netics of cefazolin in the rat, an antibiotic with non-liner
protein binding. Although this PBPK analysis by Tsuji et.
al. [6] is one the most complete and extensive in the liter-
ature, it was assumed that cefazolin was flow limited and
did not include a permeability limitation. PKQuest is the
first PBPK that allows for the combination of both non-
linear binding and a permeability limitation. PKQuest has
also reduced the number of parameters that must be en-
tered to characterize the protein binding. The extravascu-
lar extracellular albumin concentration in the different
organs (cProt [i]) relative to the albumin concentration in
plasma (cProt [vein]) has been preprogrammed (these
values are based primarily on the measurements of Tsuji
et. al. [6] for the rat). Assuming that the protein binding
in the different organs is proportional to the albumin con-
centration, the user needs to enter just the binding param-
eters for plasma and PKQuest will then automatically
determine the corresponding binding parameters for all
the organs.
The following sections will present a detailed description
of the application of PKQuest to the human pharmacoki-
netics of dicloxacillin and ceftriaxone. For this analysis it
is useful to establish a reference PS value for a solute that
is known to be permeability limited. For this reason,
PKQuest will first be used to determine the capillary per-
meability of inulin, a large water soluble molecule that is
known to be capillary limited [5].
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Methods
PBPK program and its assumptions
PKQuest [1] was used for all the analysis in this paper. The
details of the implementation of the program and a com-
plete derivation of the pharmacokinetic equations is de-
scribed in [1]. It is assumed that each organ can be
modeled as a single well-stirred compartment. This is
clearly an approximation and effects such a diffusion gra-
dients, countercurrent exchange and heterogeneous organ
blood flows [7–9] will produce small deviations from this
assumption.
The free water solute concentration (c, moles/liter) plays
a central role in these calculations because the rate of ex-
change across the capillary depends on differences in the
value of c between the capillary and tissue (see eq. 1). For
the blood or any organ, the free concentration can be re-
lated to the total (measured) concentration (Ctot, moles/
Kg) by the relation Ctot = c wfract/fw where wfract (liters/
Kg) is the water fraction in the organ and fw is the fraction
of the solute that is free in the water phase. The parameter
fwi, the fraction free in organ i (including vascular com-
partments), characterizes the fraction free (and bound)
and the corresponding tissue/blood partition coefficients.
Solute binding is a ubiquitous aspect of pharmacokinetics
and PKQuest has provided a number of different proce-
dures for handling it. For example, the propranolol phar-
macokinetics [1] were described in terms of "ktiss"
(tissue/blood partition coefficients) and "freepl" (the frac-
tion free in plasma). In the application of PKQuest to the
volatile solutes [3], fw was described in terms of "Kfwat"
(oil/water partition coefficient) and "klipi" (the fraction
of lipid in each organ).
For the protein bound antibiotics it will be assumed that
the value of fwi for organ i can be described by the single
site Scatchard type binding equation (see [1] for details):
where ci is the free concentration in organ i, k is the pro-
tein binding constant and Pbi is the concentration of pro-
tein binding sites in organ i. For the special case of linear
binding (no saturation), kci<<1, eq. 3 reduces to
As is the case for other beta-lactam antibiotics [6,10], it
will also be assumed that albumin is the binding protein
so that the protein binding site concentration in organ i
(Pbi) is proportional to the extravascular albumin concen-
tration in organ i. In PKQuest, the default values for the
tissue protein concentrations (cProti) relative to plasma
have been preprogrammed. These values are based prima-
rily on the measurements of Tsuji et. al. [6] for the rat.
(The user can change these values by entering values for
cProti.) Only the experimental value of Pb of plasma
needs to be entered in PKQuest and the value of Pbi for
the different organs are then calculated using these stored
default values.
For the general case (eq. 3), the PKQuest protein binding
is characterized by 2 parameters: kProt (the binding con-
stant, k) and cProtvein (the concentration of binding sites
in venous plasma, Pb). The special case of linear albumin
binding is completely described by just the one parameter
k*Pb (see eq. 4). In PKQuest, the linear case is turned on
by entering fw [vein] (the fraction free in the vein plasma,
which is independent of concentration) and setting kProt
= -2 and the following procedure is used to find the de-
fault values of fwi for each organ i. First, eq. 4 for i=vein is
solved for the value of kPbvein. Then, using the default val-
ues of albumin concentration in each organ (cProt [i]),
the value of kPbi is found, and, from eq. 4, the corre-
sponding fwi determined.
Experimental pharmacokinetic data
Three set of data from previous publications were used.
The data for inulin was based on the experimental meas-
urements of Odeh et. al. [11] in which the venous plasma
inulin was measured following a 5 minute, constant intra-
venous infusion of 4 gm of inulin. The data from subject
#1 was used (42 year old normal female, weight 87.3 Kg,
height 173 cm). The data for dicloxacillin was obtained
from the measurements of Lofgren et. al. [12] of the ve-
nous plasma time course following a 30 minute constant
infusion of 2 gms dicloxacillin. The averaged data from 6
young males (average weight 75 Kg) was used. The data
for ceftriaxone was obtained from the measurements of
Stoeckel and colleaques [13,14]. The data are for a single
subject (M.Fl.) given 4 different IV doses of ceftriaxone –
0.15, 0.5, 1.5 and 3 gms as a 5 minute constant infusion.
The experimental data points were obtained by using UN-
SCAN-IT (Silk Scientific Corporation) to read the data
from the published figures. All the figures shown in this
paper are direct copies (in jpeg format) of standard
PKQuest output.
Standard human parameters
The default standard values ("standardhuman") are
stored as a Maple procedure in PKQuest. The values used
for organ flows, volumes, etc. are identical to those used
in all the other applications of PKQuest [1–3]. Table 1I
lists the values of organ weight and the blood flow per or-
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gan weight for each organ for the standard human (70
Kg). These organ weights are for the default value of 20%
body fat. They are scaled depending on the value of "Fat"
that is input. The "portal" compartment corresponds to all
the organs drained by the portal vein (stomach, small and
large intestine, pancreas and spleen) with a blood flow
equal to that in the portal vein. The "liver" blood flow cor-
responds to the hepatic artery. The compartment labeled
"other" groups all the other organs with a flow and weight
adjusted to account for the total body weight (70 Kg) and
the total default cardiac output (6.06 liters/min). For a
complete listing of all parameters and constants used in
PKQuest, download the file gensolve.mws from the
PKQuest web site  [http:\\www.pkquest.com] and view
the routines "standardman()" and "defaultpar()".
Results
Inulin
As described previously [1], the PBPK data unique to each
solute is input to PKQuest in the form a short Maple  [ht-
tp:\\www.maplesoft.com] procedure that completely
characterizes the pharmacokinetics:
inulin:=proc()
defaultpar():
Wtot:=87.3;
standardhuman(Wtot);
Fat:=0.28; # 26% Fat by weight based on 173 cm height.
mecf:=1.0; # Inulin distributes only in default extracellular
fclear [muscle]:=0.354; # permeability value for muscle, all
other organs set from it
rclr:=0.1; #Renal water clearance of 0.10 liters/min
cunit:="milligrams"; #unit used in printed and plotted output
concunit [vein]:=4;# input data = venous plasma concentra-
tion
ninput:=1; finput[1]:=table([organ=vein, type=1, rate=800,
tbeg=0,
tend=5, csteady=0, padjust=0]); # 5 minute constant infu-
sion of 4000 mg
The experimental data was for the subject in fig. 2 of Odeh
et. al. [11] (this female had a weight and height of 87.3 Kg
and 173 cm, and a predicted 28% fat content). There are
3 parameters that specifically characterize inulin: mecf,
rclr, and fclear [muscle]:
The parameter mecf determines the extravascular volume
of distribution. The default value is mecf = -1, which indi-
cates that the solute distributes in all the body water. If
mecf is >0 then the solute distributes in organ i in a water
volume equal to mecf*ecf [i] where ecf [i] is the default ex-
tracellular space for organ i. The user has the option to ei-
ther adjust each of the individual values of ecf [i], or scale
all the values by the factor mecf. The default ecf [i] values
in "standardhuman" were initially set equal to the values
directly determined in the rat by Tsuji et. al. [6] from
steady state tissue inulin measurements. Then, the value
of mecf that optimized the fit to this data of Odeh et. al.
was determined, and these new values were chosen for
"standardhuman". (The human values were 16% larger
Table 1: Organ weights and blood flows for standard human (70 
Kg, 20% fat)
Organ Weight (Kg) Blood Flow (lit/min/Kg)
Artery 1.1 ----
Vein 4.4 ----
Liver 1.8 0.25 (hepatic artery)
Portal 1.5 0.75 (portal vein)
Kidney 0.31 4.0
muscle 33.0 0.0266
brain 1.4 0.56
heart 0.33 0.8
lung 0.536 14.98
skin 2.6 0.12
fat 14 0.056
"other" 4.12 0.054
"bone" 4.90. 0.0
Figure 1
Comparison of the model prediction (solid line) and the
experimental data (squares) for inulin venous plasma concen-
tration.BMC Clinical Pharmacology 2002, 2 http://www.biomedcentral.com/1472-6904/2/7
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than the rat values). Since the default data was chosen to
fit this data, setting mecf = 1 simply selects this optimized
data.
The parameter rclr is the free water concentration renal
clearance. It is equal to the volume of blood water cleared
per min (liters/min). It differs slightly from the standard
renal clearance which is equal to plasma volume/min (rclr
= 0.94  plasma clearance). The value of rclr of 0.1 liter/
min corresponds to the value directly measured by Odeh
et. al. for this subject.
The user has two different options for entering the values
of fclear [i] (see eq. 1). If, as in this case, just the value of
fclear [muscle] is input, then PKQuest will, by default, use
the relation in eq. 2 to determine the value of PSmuscle; use
the default ratios of PSi/PSmuscle to determine the value of
PSi for the other organs, and then use eq. 2 to find the cor-
responding flcear [i] for the other organs. The default ra-
tios PSi/PSmuscle assume, for example, that the liver and
kidney have a high permeability and are flow limited,
while, because of the blood brain barrier, the brain capil-
lary permeability is zero. The user can also individually in-
put the value of fclear [i] for any organ i. If an organ's
value for fclear is not set, then PKQuest will use the value
set from the above calculation based on the muscle value.
The parameter fclear [muscle] was adjusted to find the
best fit to the inulin data using the Powell minimization
feature of PKQuest [1]. The optimal value of fclearmuscle
was 0.354.
Figure 1 shows the PKQuest output for this inulin data (all
the figures in this paper are copied directly from the stand-
ard output of PKQuest). There is good agreement between
the predicted venous plasma concentration (solid line)
and the experimental values (squares). PKQuest also rou-
tinely outputs the experimental pharmacokinetic clear-
ance and volume of distribution determined from the first
and second moments of the plasma concentration extrap-
olated exponentially to infinite time [15]. These experi-
mentally derived values are in good agreement with the
model values: Plasma clearance: 0.104 liters/min (experi-
mental) versus 0.1 (model); Volume of distribution: 10.7
liters (experimental) versus 10.7 (model). PKQuest also
outputs the values of fclear [i] and the corresponding val-
ue of PSi determined from eq. 2. The fclear [muscle] of
0.354 corresponds to a PS of muscle of 0.6 ml/min/100
gm.
Dicloxacillin
Approximately 97% of human serum dicloxacillin is pro-
tein bound (fwB = 0.03) [16], making it a likely candidate
to show some permeability limitation. Another advantage
of dicloxacillin is that this binding is linear, showing no
evidence of saturation at concentrations up to 230 mg/lit-
er [6,16], simplifying the PBPK. Since the binding does
not saturate, it can be described by eq. 4 and the binding
is characterized by the single parameter fw [vein] (see
Methods).
The complete Maple procedure for dicloxacillin is:
dicloxacillin:=proc()
defaultpar():
Wtot:=75.0;
standardhuman(Wtot);
Fat:=0.16;
concunit [vein]:=4;
mecf:=1.0;
Figure 2
Comparison of the model prediction (solid line) and the experimental data (squares) for dicloxacillin venous plasma concentra-
tion. Left panel: Capillary permeability limitation (fclearmuscle 0.26). Right panel: Flow limited – no permeability limitation
(fclearmuscle = 1.0).BMC Clinical Pharmacology 2002, 2 http://www.biomedcentral.com/1472-6904/2/7
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kProt:=-2; #this turns on use of cProt [i] to determine fw [i]
fw [vein]:=0.03;
rclr:=0.12; # renal filtraton clearance
Tclr [kidney]:=3.0;# Renal tubule secretion clearance
fclear [muscle]:=0.26;
ninput:=1; finput[1]:=table([organ=vein, type=1,
rate=2000.0/30, tbeg=0,
tend=30, csteady=0, padjust=0]); # constant 30 minute in-
fusion of 2 gms
The data of Lofgren et. al. [12] for the venous plasma time
course of normal young males given a 30 minute constant
infusion of 2 gms dicloxacillin was used as input. The av-
erage body weight for this group was 75 Kg, and the stand-
ard fat content for young males (16%, [17]) was assumed.
The parameter mecf is set = 1 because dicloxacillin, like in-
ulin, distributes only in the extracellular space as shown
by its negligible distribution into red cells and its low
blood/tissue partition coefficient [6]. This means that di-
cloxacillin has the same volume of distributions in the dif-
ferent organs as was used above for inulin. Dicloxacillin is
cleared primarily by the kidney in these subjects [12] and
there is a large component of renal tubular secretion that
is blocked by probenecid [18] determined by the parame-
ter Tclr [kidney]. (Other studies have indicated that the
liver can account for 40% or more of the total clearance
[16]. PKQuest calculations (not shown) based on the as-
sumption that the clearance was divided equally between
the kidney and liver yield almost identical results). The
value of renal filtration (rclr) was set to the normal value
of 0.12 liters/min. The capillary permeability limitation is
characterized by the single parameter fclear [muscle]
(from which the permeabililty of the other organs is cal-
culated by PKQuest). The above values of Tclr [kidney] =
3.0 (liters/min) and fclear [muscle]:= 0.26 (dimension-
less) were obtained by simultaneously optimizing both
values using the Powell minimization procedure in
PKQuest [1] to find the values that provided the best fit to
the experimental data.
The left hand panel in figure 2 shows a comparison of the
PKQuest model predictions (solid line) for this set of in-
put parameters with the experimental data of Lofgren et.
al. [12]. Again, the agreement is quite good. This model fit
used a permeability limitation (fclear) for muscle of 0.26.
This means that the venous blood leaving the muscle is
26% equilibrated with the tissue. Using eq. 2, this corre-
sponds to a PSmuscle of 13 ml/min/100 gm.
The right hand panel in figure 2 shows the best fit that can
be found for this same data, assuming that dicloxacillin is
flow limited (fclear = 1). The fit is clearly worse, especially
at the early time points where a permeability limitation
should be important. Part of the better fit may have result-
ed from adjusting 2 parameters (fclear [muscle] and Tclr
[kidney]) for fig. 2 (left), while, in fig. 2 (right), only one
parameter was adjusted (Tclr [kidney]). However, the fact
that the fit in fig. 2 (right) could not be significantly im-
proved by trying to adjust other parameters, such as mus-
cle blood flow, extracellular space and/or plasma protein
binding, suggests that this permeability limitation is real.
Ceftriaxone
In addition to having a high degree of protein binding,
Ceftriaxone has the additional complication that this
binding is non-linear and saturates at high concentra-
tions. Stoeckel and colleagues have carried out detailed in-
vestigations of the pharmacokinetics of ceftriaxone in
humans and the influence of this non-linear binding
[13,14]. They showed that the non-linear kinetics of ceftri-
axone arise solely from this non-linear binding by dem-
onstrating that the kinetics became linear if the free drug
concentrations are used in the pharmacokinetic calcula-
tions. In this section, PKQuest will be used to develop a
PBPK model for this data. The model includes both non-
linear binding and a permeability limitation, the first time
that both these factors have been included in a PBPK.
Because the protein binding saturates, the general Scatch-
ard binding equation (eq. 3) must be used. This requires
a value for the protein binding constant (k) and the con-
centration of binding sites in each organ (Pbi). As de-
scribed above (Methods), these constants are determined
by two PKQuest parameters: kProt (the association con-
stant for protein binding) and cProt [vein] (the plasma
concentration of binding sites). PKQuest then uses the de-
fault information about the tissue albumin concentration
in each organ relative to the plasma albumin to determine
the concentration of binding sites in each organ (Pbi). The
data of Stoeckel et. al. [13,14] are ideal for this analysis be-
cause they provide information about the venous blood
levels for the same subject (M.Fl.) given 4 different IV dos-
es of ceftriaxone – 0.15, 0.5, 1.5 and 3 gms. It is important
to have these different inputs in order to test if the PBPK
can accurately model the non-linear kinetics. Since all the
doses were given to the same subject, an identical set of
PBPK parameters is used for all the doses:
ceftriaxone:=proc()
defaultpar():
Wtot:=70.0; #Body weightBMC Clinical Pharmacology 2002, 2 http://www.biomedcentral.com/1472-6904/2/7
Page 7 of 11
(page number not for citation purposes)
standardhuman(Wtot);
Fat:=0.18;# Fat body weight fraction for 70 Kg, 183 cm
man.
cunit:="micromoles";
concunit [vein]:=4;# input = venous plasma concentration
mecf:=0.85; # distribute only in extracellular space – adjust-
ed to fit data
fclear [muscle]:=0.15; # determinse muscle capillary perme-
ability
rclr:=0.11; # Normal renal clearance
Tclr [kidney]:=0.035; # Renal tubule secretion
Tclr [liver]:=0.06; # Liver metabolism
cProt [vein]:=806; # total conc. protein binding site in plas-
ma (micromoles/liter)
kProt:=0.0315; # Association constant (liters/micromoles)
Subject M.Fl. had a weight of 70 Kg and height of 183 cm
(K. Stoeckel, personal communication). The values of
cProt [vein] and kProt used above are the values deter-
mined by equilibrium dialysis for the subject M.Fl. [13].
Ceftriaxone is eliminated by both renal secretion and liver
metabolism. The normal value of 0.ll liters/min was used
for renal clearance, and the tubule secretion (Tclr [kid-
Figure 3
Comparison of the capillary permeability limited model prediction (solid line) and the experimental data (squares) for ceftriax-
one venous plasma concentrations. The four panels correspond to inputs of 0.15, 0.5, 1.5 and 3.0 grams given as a 5 minute
constant IV infusion. Because the protein binding saturates, the effective capillary permeability limitation (fclear) decreases as
the concentration increases.BMC Clinical Pharmacology 2002, 2 http://www.biomedcentral.com/1472-6904/2/7
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ney]) and liver metabolism (Tclr [liver]) were adjusted to
have a renal clearance of about 65% of the total clearance
as was observed experimentally. The liver metabolism and
tubule secretion were assumed to be linear because the ki-
netics were linear if corrections were made for the plasma
binding. The value mecf has been set to 0.85 to slightly
improve the fit to the data. This makes the extracellular
volume of distribution 85% of the default value. It is not
clear whether this has some physiological significance for
this subject or if it is just a "fudge" factor that corrects for
some other limitation in the PBPK. The two parameters
fclear [muscle] and Tclr [liver] were simultaneously ad-
justed using the Powell minimization procedure in
PKQuest to obtain the best fit to the experimental data.
For this case, where the binding is non-linear, the value of
fclear [muscle] that is input is interpreted as the value of
fclear in the limit of zero concentration. As the concentra-
tion increases, the value of the fraction free (fwB) will in-
crease (eq. 3) and the corresponding value of fclear (eq. 2)
will also increase (i.e. become less permeability limited).
The optimized value of fclear [muscle] of 0.15 corre-
sponds (see eq. 2) to a PSmuscle of 6 ml/min/100 gm.
Figure 3 shows the agreement between the model predic-
tions of PKQuest and the experimental data for inputs of
0.15, 0.5, 1.5 and 3.0 grams. The same parameter set was
used for each of these 4 fits. Only the input function was
varied. Over the plasma concentration ranges seen at early
times for each of the 4 doses, the fraction free in the blood
and the fclearmuscle (fraction of solute that equilibrates
with the tissue in one pass through the muscle capillary)
varies as follows: At 0 M: fraction free = 0.038, fclear =
0.15; At 50 M: fraction free = 0.092, fclear = 0.33; At 150
M: fraction free = 0.18, fclear = 0.55; At 450 M: fraction
free = 0.374, fclear = 0.8; At 800 M: fraction free = 0.51;
fclear = 0.89. The non-linearity in the kinetics is apparent
both in the changes in the qualitative shape of the curve
and in the absolute values of the plasma concentration.
The agreement between the model and experiment for
this 20 fold dose range and roughly 10 fold range of frac-
tion free is surprisingly good, especially considering that
there are so few adjustable parameters (see below).
Figure 4 show the corresponding fits for the case where
ceftriaxone is assumed to be flow limited (fclear = 1) for
the 0.15 and 3.0 gm dose. Comparing figures 3 and 4 it
can be seen that the permeability limitation significantly
influences the pharmacokinetics only for the lower doses
because of the saturation of the protein binding. For the
low dose (0.15 grams), the plasma concentration at early
times is about 50 M which will have a corresponding
fclear of 0.33. This means that there will be only 33%
equilibration during one pass through the capillary – a
significant permeability limitation. However, for the high
dose (3.0 grams), the early plasma concentration is about
800 M which corresponds to a fclear of 0.89 which dif-
fers only sightly from the flow limited condition (fclear =
1) assumed for figure 4.
Discussion and Conclusions
The definition that is introduced in this paper for capil-
lary-tissue clearance (fclear, eq. 1) and its relation to the
fraction free in tissue (fwB, eq. 2) is not new. These defini-
tions are identical to the classical expressions used to de-
scribe pulmonary diffusion capacity of a gas where fwB
corresponds to the inverse of the gas solubililty () [19].
Figure 4
Comparison of the flow limited model prediction (solid line) and the experimental data (squares) for ceftriaxone venous
plasma concentrations. Left panal: 0.15 gm IV input; Right panel: 3.0 gm input.BMC Clinical Pharmacology 2002, 2 http://www.biomedcentral.com/1472-6904/2/7
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The capillary permeability limitation produced by the
protein binding of dicloxacillin and ceftriaxone described
in this paper is directly analogous to the carbon monoxide
pulmonary diffusion limitation that results from its high
blood solubility. This analogy has not been previously
recognized for the protein bound antibiotics.
The value of PSmuscle of inulin determined above is a
measure of the capillary permeability averaged over all the
muscles. It represents the permeability for the muscle in
the condition of these measurements – the resting human
with a relatively low muscle blood flow (default value =
0.0266 liters/min/Kg). Surprisingly, this may be the first
report of this value in humans. The value of PSmuscle
found here for inulin of 0.6 ml/min/100 gm is slightly less
than the reported value of 0.9 for lightly exercising in vivo
human forearm muscle [20] and is in the range reported
for animal measurements (0.6 to 1.2; [5]). The literature
values are for muscles with 2 to 4 times the default blood
flow assumed for these measurements. Since the muscle
capillary surface area (S) can vary by a factor of more than
4 as capillaries are recruited at higher flows [5], this low
resting blood flow could easily account for the low PS in-
ulin value obtained in this analysis.
The values of PSmuscle for dicloxacillin and ceftriaxone es-
timated here are the first measurements of the capillary
permeability for any antibiotic. In fact, as discussed
above, it had always been assumed previously that these
drugs were flow limited, which would mean that their per-
meability was so large that it could not be measured.
These drugs do, in fact, have a high intrinsic permeability.
For example, the value of PSmuscle found for dicloxacillin
of 13 ml/min/100 gm is a very high permeability and, if it
were not protein bound (and fwB equaled 1), would cor-
respond to an fclear [muscle] of 0.999 (see eq. 2) – i.e. it
would be flow limited. The only reason that it is not flow
limited and that its value can be measured is because of its
high protein binding, with a fwB of 0.03. The value of PS-
muscle found for ceftriaxone (6 ml/min/100 gm) is about
half the dicloxacillin value.
The PSmuscle values for the antibiotics are about 10 times
larger than the PS value of inulin. If these antibiotics were
lipid impermeable and had to cross the capillary via the
interendothelial cell slits, their permeability should be de-
termined simply by their molecular radius [5], and they
should have a permeability similar to that of sucrose or
EDTA, molecules with similar molecular radii. The antibi-
otic skeletal muscle capillary permeabilities found here
are about 2 times larger than those reported for sucrose
and EDTA [5]. It has recently been shown that the -
Lactam antibiotics are transported across the intestinal ep-
ithelial cells via the peptide transport system [21]. This rel-
atively high capillary permeability for these antibiotics
may indicate that this system is also present in the capil-
lary endothelium.
Does this capillary permeability limitation have any prac-
tical significance in terms of therapeutics? The anti-infec-
Figure 5
Free plasma (red) and tissue (black) water ceftriaxone concentration. The dashed lines correspond to the flow limited model
results and the solid lines are for the case of a capillary permeability limitation. The PBPK parameters and input conditions are
identical to those used in figs. 3 and 4.BMC Clinical Pharmacology 2002, 2 http://www.biomedcentral.com/1472-6904/2/7
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tive activity of the antibiotic should be roughly equivalent
to the free concentration in the tissue water [22]. Figure 5
contrasts the time course of the free ceftriaxone concentra-
tion in the extracellular muscle (black) and plasma (red)
water for the permeability limited (solid line) and flow
limited (dashed line) cases. For the low dose (0.15 gram)
where the protein binding is high and the permeability
limitation is at its maximum, the muscle water antibiotic
concentration for the permeability limited case (black sol-
id line) is significantly less than for the flow limited case
(black dashed line) for the first 30 minutes. After 40 min-
utes the muscle tissue concentrations for the permeability
limited and flow limited cases are not significantly differ-
ent. At the high dose (3.0 gram), there is no significant dif-
ference even at early times. Thus, from a therapeutic
viewpoint, this permeability limitation is probably not
important.
This inference of a capillary permeability limitation is in-
direct since it is based only on a theoretical analysis of the
experimental plasma pharmacokinetics. The analysis
shown in fig. 5 suggests that it should be possible directly
observe the effects of this permeability limitation from si-
multaneous measurements of the free water concentra-
tion in the plasma and muscle. The low dose (0.15 gram)
panel in fig. 5 shows that the capillary permeability limi-
tation creates a large difference between the plasma (red
line) and muscle (black line) free water concentration
during the first 30 minutes. Kovar et. al. [22] measured the
ceftriaxone free plasma and muscle water using microdial-
ysis in the rat for doses of 50 and 100 mg/Kg. They com-
pared their experimental measurements with theoretical
pharmacokinetic curves based on the flow limited as-
sumption. For the low dose (where binding and permea-
bility limitation will be higher) the experimental muscle
water concentration at 50 minutes was significantly less
(about 40%) than the flow limited prediction and this dif-
ference became insignificant by 100 minutes. Similarly,
the muscle tissue measurements of Tsuji et. al. [6] of ce-
fazolin (another protein bound antibiotic) were signifi-
cantly less than the flow limited predictions for the first
100 minutes. Although both of these results are consistent
with a capillary permeability limitation, they are probably
not conclusive because of the large scatter in the measure-
ments and the inherent uncertainties and limited time res-
olution of the tissue measurements.
The PBPK for ceftriaxone discussed in this paper would
normally be thought of as very "difficult" or "complicat-
ed". The model requires information for each organ about
the extravascular volumes of distribution, protein binding
constants, capillary permeability, weights and blood
flows, in addition to information about renal clearance,
tubular secretion and hepatic metabolism. One would ex-
pect that, with this many parameters, it would be impos-
sible to have any confidence in the PBPK parameters that
are found. However, because of the basic design feature of
PKQuest, there are actually only 6 parameters that are spe-
cifically required to completely characterize ceftriaxone
(rclr, Tclr [liver], Tclr [kidney], cProt [vein] and kProt; see
the ceftriaxone procedure above). Two of these parame-
ters were measured experimentally (cProt [vein] and
kProt) and the value of rclr (renal plasma clearance) was
set to the default human value. Since the ratio of liver to
renal clearance is known experimentally, only one of the
parameters Tclr [liver] and Tclr [kidney] is independent.
This leaves just two adjustable parameters (fclear [muscle]
and Tclr [liver]). In addition, it may be necessary to slight-
ly adjust some of the default parameters (e.g. mecf for the
ceftriaxone case) to optimize the fit.
These PBPK studies provide a good example of the major
difference of philosophy between PKQuest and the usual
PBPK. For example, in the rat PBPK developed by Tsuji et.
al. [6] for cefazolin, nearly every PBPK parameter required
by the model was directly measured, including steady
state extravascular volumes of distribution in the different
organs, organ blood flows and weights, renal and hepatic
clearance, time dependence of cefazolin concentration in
the different organs, etc. This approach is, for obvious rea-
sons, impossible for human studies. The basic philosophy
of PKQuest is that it is not necessary to make these meas-
urements for each drug that is investigated if the PBPK has
been previously tested and refined using a large variety of
compounds, combined with information available in the
literature. For example, for these studies, the extracellular
volumes of distribution (ecf) determined in the inulin
PBPK analysis have been used as the default values for the
antibiotic studies. As PKQuest is applied to other com-
pounds, these "default" value will be improved and mod-
ified. The more that PKQuest is used, the more reliable are
its values and the more confidence one can place in its re-
sults.
The major design feature of PKQuest, which is to mini-
mize the number of input parameters required from the
user, and maximize the use of previously determined in-
formation, supports this philosophy. For example, the
user only needs to enter the value of fclear [muscle] and
PKQuest uses the previously determined ratios of PSi/PS-
muscle to set all the other organ permeabilities. As another
example, the user need only enter the one parameter mecf
to set all the extracellular volumes for each organ and the
user knows that a mecf of 1 corresponds to the standard
default human set of values. If the user wanted, e.g. to
make the ecf of muscle 10% larger than the default, it is
only necessary to enter ecf [muscle] = 1.1*ecf [muscle]
and the user does not need to know the actual default val-
ue. This not only makes PKQuest easier to use, but it also
improves the validity of the final PBPK because the userBMC Clinical Pharmacology 2002, 2 http://www.biomedcentral.com/1472-6904/2/7
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has confidence that the best estimates based on previous
applications of PKQuest are being used.
The PKQuest program and all of the examples used in this
paper are freely available on the Web at  [ht-
tp:\\www.pkquest.com].
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